From obesity through gut microbiota to cardiovascular diseases: a dangerous journey

Paolo Marzullo, Laura Di Renzo, Gabriella Pugliese, Martina De Siena, Luigi Barrea, Giovanna Muscogiuri, Annamaria Colao, Silvia Savastano, on behalf of Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group
{"title":"From obesity through gut microbiota to cardiovascular diseases: a dangerous journey","authors":"Paolo Marzullo, Laura Di Renzo, Gabriella Pugliese, Martina De Siena, Luigi Barrea, Giovanna Muscogiuri, Annamaria Colao, Silvia Savastano, on behalf of Obesity Programs of nutrition, Education, Research and Assessment (OPERA) Group","doi":"10.1038/s41367-020-0017-1","DOIUrl":null,"url":null,"abstract":"The co-existence of humans and gut microbiota started millions of years ago. Until now, a balance gradually developed between gut bacteria and their hosts. It is now recognized that gut microbiota are key to form adequate immune and metabolic functions and, more in general, for the maintenance of good health. Gut microbiota are established before birth under the influence of maternal nutrition and metabolic status, which can impact the future metabolic risk of the offspring in terms of obesity, diabetes, and cardiometabolic disorders during the lifespan. Obesity and diabetes are prone to disrupt the gut microbiota and alter the gut barrier permeability, leading to metabolic endotoxaemia with its detrimental consequences on health. Specific bacterial sequences are now viewed as peculiar signatures of the metabolic syndrome across life stages in each individual, and are linked to pathogenesis of cardiovascular diseases (CVDs) via metabolic products (metabolites) and immune modulation. These mechanisms have been linked, in association with abnormalities in microbial richness and diversity, to an increased risk of developing arterial hypertension, systemic inflammation, nonalcoholic fatty liver disease, coronary artery disease, chronic kidney disease, and heart failure. Emerging strategies for the manipulation of intestinal microbiota represent a promising therapeutic option for the prevention and treatment of CVD especially in individuals prone to CV events.","PeriodicalId":14202,"journal":{"name":"International journal of obesity supplements","volume":"10 1","pages":"35-49"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41367-020-0017-1","citationCount":"30","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of obesity supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s41367-020-0017-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 30

Abstract

The co-existence of humans and gut microbiota started millions of years ago. Until now, a balance gradually developed between gut bacteria and their hosts. It is now recognized that gut microbiota are key to form adequate immune and metabolic functions and, more in general, for the maintenance of good health. Gut microbiota are established before birth under the influence of maternal nutrition and metabolic status, which can impact the future metabolic risk of the offspring in terms of obesity, diabetes, and cardiometabolic disorders during the lifespan. Obesity and diabetes are prone to disrupt the gut microbiota and alter the gut barrier permeability, leading to metabolic endotoxaemia with its detrimental consequences on health. Specific bacterial sequences are now viewed as peculiar signatures of the metabolic syndrome across life stages in each individual, and are linked to pathogenesis of cardiovascular diseases (CVDs) via metabolic products (metabolites) and immune modulation. These mechanisms have been linked, in association with abnormalities in microbial richness and diversity, to an increased risk of developing arterial hypertension, systemic inflammation, nonalcoholic fatty liver disease, coronary artery disease, chronic kidney disease, and heart failure. Emerging strategies for the manipulation of intestinal microbiota represent a promising therapeutic option for the prevention and treatment of CVD especially in individuals prone to CV events.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从肥胖症到肠道微生物群,再到心血管疾病:一段危险的旅程
人类与肠道微生物群的共存始于数百万年前。直到现在,肠道细菌和宿主之间逐渐形成了一种平衡。现在,人们已经认识到,肠道微生物群是形成适当的免疫和新陈代谢功能的关键,更广泛地说,是维持健康的关键。肠道微生物群在出生前就在母体营养和新陈代谢状态的影响下建立起来了,这会影响后代未来的新陈代谢风险,如肥胖、糖尿病和一生中的心脏代谢紊乱。肥胖和糖尿病容易破坏肠道微生物群,改变肠道屏障的通透性,导致代谢性内毒素血症,对健康造成不利影响。目前,特定的细菌序列被视为每个人不同生命阶段代谢综合征的特殊标志,并通过代谢产物(代谢物)和免疫调节与心血管疾病(CVDs)的发病机制有关。这些机制与微生物丰富度和多样性异常有关,增加了患动脉高血压、全身炎症、非酒精性脂肪肝、冠状动脉疾病、慢性肾病和心力衰竭的风险。操纵肠道微生物群的新策略是预防和治疗心血管疾病(尤其是容易发生心血管疾病的人群)的一种很有前景的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cardiovascular effects of antiobesity drugs: are the new medicines all the same? Maternal obesity: focus on offspring cardiometabolic outcomes What is the best diet for cardiovascular wellness? A comparison of different nutritional models Sleep disturbances: one of the culprits of obesity-related cardiovascular risk? From obesity through gut microbiota to cardiovascular diseases: a dangerous journey
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1